Clinical Trial Update: The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the cardiac effects of empagliflozin in patients at high risk of heart failure. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Obesity

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Jacob Moller | Conditions: Heart Failure, Obesity | Phase 2 | Status: COMPLETED